SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3
Sellas (SLS) fell 17.2% this week after a key trial milestone. ImmunityBio (IBRX) declined despite FDA approvals. Ionis (IOVA) also slumped. SLS CEO called the milestone critical, but results are pending. IBRX has a Q4 FDA submission planned. Retail sentiment varied; all three stocks outperformed XBI this year.
How this was made
The 30-second read
Why it matters
The trial milestone for Sellas is the primary new fact; the other two companies have no fresh corporate events beyond upcoming trial readouts.
Market read
Trial milestones and upcoming readouts create short‑term price pressure for the three stocks, with Sellas experiencing the sharpest decline.
What to watch
Potential partnership or licensing deals not mentioned could offset trial uncertainty.
Background
The article reports recent trial milestones for three biotech companies and summarizes retail sentiment on Stocktwits.
Ticker impact
Sellas (SLS) fell 15% after its Phase 3 Regal trial reached the 80th death event, a milestone that did not improve outlook.
likely further downside as market prices in uncertainty over overall survival benefit
No efficacy data released; the 80th death event signals a potential safety concern and delays any positive readout.
ImmunityBio (IBRX) slid despite FDA expansion of Anktiva plus BCG approval and a pending readout from the Quilt‑2.005 trial in November.
moderate pressure ahead of the November readout
The trial readout is a near‑term catalyst; without data, the market remains cautious.
Iovance Biotherapeutics (IOVA) showed bearish sentiment on Stocktwits while the other two biotech stocks rallied.
potential further decline if negative sentiment persists
No specific corporate news for IOVA; sentiment alone may drive modest downside.
Market effects
Biotech sector may see heightened volatility as trial milestones and upcoming readouts dominate investor focus.
U.S. biotech stocks impacted; no broader regional effect.
Limited to investors tracking biotech pipelines.
Counterpoint
If the upcoming trial data exceed expectations, the current sell‑off could be a buying opportunity.
Key entities
- companySellas Life Sciences
Biotech firm conducting Phase 3 Regal leukemia trial.
- companyImmunityBio
Biotech firm with FDA‑expanded Anktiva plus BCG indication.
- companyIovance Biotherapeutics
Biotech firm referenced for retail sentiment.
